Hero background mobile

JYNARQUE® (tolvaptan) is proven to slow kidney function
decline in adults at risk for rapidly progressing ADPKD.

JYNARQUE can cause serious liver problems that can lead
to the need for liver transplant or can lead to death.

ADPKD logo

Register for an Autosomal
Dominant Polycystic Kidney Disease
(ADPKD) Peer Conversations event now.

ADPKD logo

Register for an Autosomal
Dominant Polycystic Kidney Disease
(ADPKD) Peer Conversations event now.

JYNARQUE® (tolvaptan) is proven to slow kidney function
decline in adults at risk for rapidly progressing ADPKD.

JYNARQUE can cause serious liver problems that can lead
to the need for liver transplant or can lead to death.

Click here for more Safety Information
Hero background
SFMC wrapper
Phone Numbers
Please input your phone number, including area code; Use a space to separate an extension from the primary phone number.
Email Addresses
OptCodes
Survey Question & Answers

ADPKD Peer Conversations is a series of webinars that provides an interactive experience for participants. In each webinar, participants will be able to discuss topics ranging from diagnosis to starting treatment on JYNARQUE® with other ADPKD patients and caregivers to those with ADPKD. Each webinar will provide participants with the opportunity to connect with other members of the ADPKD community in their region through interactive Q&As and helpful conversations.

Registration and Contact Information

The personal information you provide below will be used only for the ADPKD Peer Conversations webinar series. To view our privacy policy, click here.

Please enter the following information, which will be used as part of the verification process for enrollment. (* = required)

(You must be 18 or older to participate in this program.)

Please select one or more of the events below:

Disease state awareness, getting diagnosed, family history
Conversations with your HCP about support systems and information you wish you'd had earlier in your disease journey
Managing symptoms, work, family, and holidays
Half width elements wrapper
(These webinars are only for patients living with rapidly progressing ADPKD and their caregivers.)

Use data for registration: I agree to my personal data being processed in this portal for the purposes of registering my interest in attending an upcoming patient program sponsored by Otsuka.

Opt-in: By clicking the "YES" button and submitting your information, you understand and agree to Otsuka America Pharmaceutical, Inc. (OAPI) Terms of Use and that OAPI or approved parties acting on its behalf may use the information you provide to send you information about JYNARQUE, including ADPKD and events in your area, and to tailor communications based on your treatment experience.

Would you like to register to receive future communications regarding educational opportunities, emails, products, and services from JYNARQUE?

I have reviewed OAPI's Terms of Use and Privacy Policy and agree to my information being used in accordance with OAPI's Privacy Policy.

For more information on how OAPI will use and protect your data, please see OAPI’s Privacy Policy. You understand that from time to time OAPI's Privacy Policy and Terms of Use may change and that you should check OAPI's website for the most recent version of the Terms of Use and Privacy Policy. You can unsubscribe from receiving OAPI marketing communications by clicking here.

For any questions about ADPKD Peer Conversations or to register by phone, please call us at 855-415-7459.

Please ensure all fields are correct before submitting.

While there will be discussion of personal health experiences, we ask that participants refrain from discussing any personally identifiable information. ADPKD Peer Conversations webinars are not designed to provide medical advice.

Talk to your doctor about specific medical questions you may have regarding treatment.

IMPORTANT SAFETY INFORMATION and INDICATION for JYNARQUE® (tolvaptan)

INDICATION:

What is JYNARQUE?

JYNARQUE is a prescription medicine used to slow kidney function decline in adults who are at risk for rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). It is not known if JYNARQUE is safe and effective in children.

IMPORTANT SAFETY INFORMATION:

  • Serious liver problems. JYNARQUE can cause serious liver problems that can lead to the need for a liver transplant or can lead to death. Stop taking JYNARQUE and call your healthcare provider right away if you get any of the following symptoms:
    • feeling tired
    • loss of appetite
    • nausea
    • right upper stomach (abdomen) pain or tenderness
    • vomiting
    • fever
    • rash
    • itching
    • yellowing of the skin and white part of the eye (jaundice)
    • dark urine

It is important that you have a blood test before you start JYNARQUE to help reduce your risk of liver problems. Your healthcare provider will do a blood test to check your liver:

  • before you start taking JYNARQUE
  • at 2 weeks and 4 weeks after you start treatment with JYNARQUE
  • then monthly for 18 months during treatment with JYNARQUE
  • and every 3 months from then on

Because of the risk of serious liver problems, JYNARQUE is only available through a restricted distribution program called the JYNARQUE Risk Evaluation and Mitigation Strategy (REMS) Program.

Do not take JYNARQUE if you:

  • have a history of liver problems or have signs or symptoms of liver problems, excluding polycystic liver disease
  • cannot feel if you are thirsty or cannot replace fluids by drinking
  • have been told that the amount of sodium (salt) in your blood is too high or too low
  • are dehydrated
  • are allergic to tolvaptan or any of the ingredients in JYNARQUE
  • are unable to urinate

Tell your healthcare provider about all your medical conditions, including if you:

  • have a history of sodium (salt) levels that are too low
  • are pregnant or plan to become pregnant. It is not known if tolvaptan will harm your unborn baby. Tell your healthcare provider if you become pregnant or think that you may be pregnant
  • are breastfeeding or plan to breastfeed. It is not known if tolvaptan passes into your breast milk. Do not breastfeed during your treatment with JYNARQUE. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

  • Taking JYNARQUE with certain medicines could cause you to have too much tolvaptan in your blood. JYNARQUE should not be taken with certain medications. Your healthcare provider can tell you if it is safe to take JYNARQUE with other medicines
  • Do not start taking a new medicine without talking to your healthcare provider

JYNARQUE may cause serious side effects, including:

  • Too much sodium in your blood (hypernatremia) and loss of too much body fluid (dehydration). In some cases, dehydration can lead to extreme loss of body fluid called hypovolemia. You should drink water when you are thirsty and throughout the day and night. Stop taking JYNARQUE and call your healthcare provider if you cannot drink enough water for any reason, such as not having access to water, or vomiting or diarrhea. Tell your healthcare provider if you get any of the following symptoms:
    • dizziness
    • fainting
    • weight loss
    • a change in the way your heart beat
    • feeling confused or weak

What should you avoid while taking JYNARQUE?

Do not drink grapefruit juice during treatment with JYNARQUE. This could cause you to have too much tolvaptan in your blood.

The most common side effects of JYNARQUE are:

  • thirst and increased fluid intake
  • making large amounts of urine, urinating often, and urinating at night

These are not all the possible side effects of JYNARQUE. Talk to your healthcare provider about any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist.

If you have any questions about your health or medicines, talk to your healthcare professional.

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 ( www.fda.gov/medwatch).

Please read FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE